Меню
Набор по приглашению NCT07704931

Pilot Study to Evaluate Changes in Intra-Epidermal Nerve Fiber Density (IENFD) in Patients With Small-Fiber Neuropathy

Без фазы С лечением Small Fiber Neuropathy

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Evoke SCS system.
Кому может быть актуально
Состояния в реестре: Small Fiber Neuropathy. Базовые параметры: от 19 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

This prospective observational pilot study will evaluate structural, functional, and patient-reported outcomes in adults with small fiber neuropathy who receive Saluda Evoke ECAP-controlled spinal cord stimulation as part of routine clinical care. The study does not assign, direct, or modify spinal cord stimulation therapy. All decisions regarding patient selection, trial stimulation, permanent implantation, and device programming are made independently by the treating physician according to standard clinical practice. The primary objective is to assess change in intra-epidermal nerve fiber density from baseline to 12 months. Secondary objectives include evaluation of quantitative sensory testing, pain intensity, patient-reported outcomes, and correlations between changes in nerve fiber density, sensory function, and neuropathic pain outcomes. The study will enroll up to 10 adult participants with clinically diagnosed small fiber neuropathy and chronic neuropathic pain. Research assessments include patient-reported outcome measures, quantitative sensory testing, review of available clinical records, and a 12-month follow-up skin biopsy for intra-epidermal nerve fiber density. This aligns with the approved protocol: observational, 10 adults, 12-month participant follow-up, primary IENFD endpoint, and secondary QST/pain/correlation endpoints.

Вмешательства

  • Устройство Evoke SCS system
    Spinal cord stimulation using the Saluda Evoke system, an ECAP-controlled closed-loop SCS device that monitors neural response and adjusts stimulation in real time. Participants receive SCS therapy as part of routine clinical care. The study observes structural, sensory, pain, and patient-reported outcomes over 12 months and does not assign, direct, or modify device use, implantation, or programming. This matches the protocol's device description and keeps the intervention generic enough for Cl

Первичные конечные точки

  • Change in Intra-Epidermal Nerve Fiber Density From Baseline to 12 Months [Срок оценки: Baseline to 12 months]
Вторичные конечные точки (5)
  • Change in Thermal Detection Thresholds From Baseline to 12 Months [Срок оценки: Baseline to 12 months]
  • Change in Numeric Pain Rating Scale Score Over 12 Months [Срок оценки: Baseline, 1 week, 3 months, 6 months, and 12 months]
  • Patient Global Impression of Change Score Over 12 Months [Срок оценки: 1-week, 3 months, 6 months, and 12 months]
  • Correlation Between Change in IENFD and Change in Quantitative Sensory Testing Thresholds [Срок оценки: Baseline to 12 months]
  • Correlation Between Change in IENFD and Change in Pain Intensity [Срок оценки: Baseline to 12 months]

Критерии участия

Критерии включения

  • Age 19 years or older.
  • Clinically diagnosed small fiber neuropathy based on abnormal intra-epidermal nerve fiber density (IENFD) skin biopsy.
  • Chronic neuropathic pain with Numeric Pain Rating Scale score of at least 6.
  • Candidate for ECAP-controlled spinal cord stimulation therapy based on the - - - Principal Investigator's medical judgment.
  • Able and willing to undergo baseline and 12-month skin biopsies.
  • Able to comply with 12-month quantitative sensory testing.
  • Able to provide informed consent.

Критерии исключения

  • Confounding factors that may independently contribute to small fiber damage or alter nerve fiber density, including uncontrolled diabetes defined as HbA1c greater than 8.5% within the last 3 months, autoimmune disorders such as lupus, or history of alcohol abuse.
  • Contraindications to spinal cord stimulation therapy, including active infection, coagulation disorders, allergy to medical device components, or other relevant surgical/device contraindications.
  • Uncontrolled medical or psychiatric conditions.
  • Pregnancy or planning to become pregnant during the study period.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

США · 1 центр
  • Grand Island Pain Relief Center — Grand Island

Идентификаторы

NCT: NCT07704931 · SAL 002

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗